Dauntless Investment Group LLC Buys New Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR)

Key Points

• Dauntless Investment Group LLC invested $515,000 in aTyr Pharma, acquiring 170,689 shares, which represent about 0.6% of its portfolio.
• JPMorgan Chase & Co. significantly increased its stake in aTyr Pharma by 467.8%, now holding 178,532 shares valued at $646,000.
• aTyr Pharma's stock has seen a recent trading increase of 5.7%, with current market conditions reflecting a market capitalization of $548.24 million.

Dauntless Investment Group LLC bought a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 170,689 shares of the company's stock, valued at approximately $515,000. aTyr Pharma accounts for about 0.6% of Dauntless Investment Group LLC's holdings, making the stock its 23rd biggest holding. Dauntless Investment Group LLC owned about 0.19% of aTyr Pharma at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ATYR. Group One Trading LLC acquired a new stake in shares of aTyr Pharma during the 4th quarter valued at $26,000. Raymond James Financial Inc. bought a new stake in shares of aTyr Pharma in the 4th quarter valued at $39,000. XTX Topco Ltd bought a new stake in shares of aTyr Pharma in the 4th quarter valued at $40,000. Two Sigma Advisers LP bought a new stake in aTyr Pharma in the 4th quarter valued at about $44,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of aTyr Pharma during the first quarter valued at about $38,000. 61.72% of the stock is owned by institutional investors.

aTyr Pharma Price Performance

Shares of NASDAQ:ATYR traded down $0.04 during trading on Friday, reaching $4.68. The company had a trading volume of 2,631,809 shares, compared to its average volume of 2,325,030. The company has a fifty day moving average of $5.21 and a two-hundred day moving average of $4.05. The stock has a market capitalization of $416.18 million, a P/E ratio of -5.81 and a beta of 0.89. aTyr Pharma, Inc. has a 12 month low of $1.67 and a 12 month high of $7.29. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Equities research analysts forecast that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ATYR shares. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wells Fargo & Company lifted their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.20.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.